Clinical trials
Bladder Cancer Recurrence clinical trials
Below are recruiting bladder cancer recurrence clinical trials, each written for real people, not researchers. We’re tracking 158 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07337850Recruiting
Testing 68Ga-FAPI PET scan in biliary cancers
This trial is testing a new type of PET scan (called 68Ga-FAPI) to see if it can better detect biliary tract cancers, including advanced or recurring gallbladder cancer and intrahepatic cholangiocarcinoma. It may help doctors find cancer more accurately, which could guide better treatment decisions.
Mumbai, MaharashtraAges 18–90 - NCT04979156Recruiting
Laser removal of bladder tumors in one piece
This trial studies using a specific laser technique to remove bladder tumors “en bloc” (in one piece) during a procedure. It may help reduce leftover tumor tissue and improve how safely the tumor can be removed for people with certain small, papillary bladder tumors.
Kansas City, KansasAges 18 years+ - NCT07030257RecruitingPhase 1/Phase 2
Study of CP-383 for advanced solid tumors
This study tests a new drug called CP-383 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow cancer growth, especially for certain cancers with genetic changes.
Denver, ColoradoAges 18 years+ - NCT06822010RecruitingPhase 2
Gemcitabine and Mitomycin for High-Risk Upper Tract Cancer
This trial tests a combination of two chemotherapy drugs, gemcitabine and mitomycin, given directly into the kidney or ureter through a thin tube. It is for people with a high-risk but non-invasive form of upper urinary tract cancer that has not spread into deeper tissues.
New Brunswick, New JerseyAges 18–99 - NCT07501650RecruitingPhase 1
Pembrolizumab plus ultrasound bubbles for head and neck cancer
This trial combines the immunotherapy drug pembrolizumab (Keytruda) with a special ultrasound technique that uses tiny bubbles to make the treatment work better. It is for people with HPV-negative head and neck cancer that has come back or spread to other parts of the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06682728RecruitingPhase 2
Treating high-risk bladder cancer after surgery
This trial tests a combination of two drugs (sacituzumab govitecan and nivolumab) given after surgery to prevent the return of muscle-invasive bladder cancer. It is for patients whose cancer has a high chance of coming back despite surgery.
Orange, CaliforniaAges 18 years+ - NCT05492136Recruiting
Radiofrequency during liver surgery to reduce cancer coming back
This study looks at whether using radiofrequency (a heat-based treatment used during surgery) during liver surgery can lower the chances that cancer returns locally. It includes people with colorectal cancer that has spread to the liver and people with liver cancer (HCC).
BarcelonaAges 18 years+ - NCT07204132Recruiting
Freezing and Immunotherapy for Bladder Cancer
This study tests a combination treatment for people with early-stage bladder cancer who want to avoid bladder removal. It uses a freezing technique (cryoablation) inside the bladder along with immunotherapy drugs to see if this can cure the cancer while keeping the bladder.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT06833073RecruitingPhase 2
Study of an mRNA vaccine and BCG for bladder cancer
This trial tests an experimental mRNA vaccine (V940) combined with BCG therapy for people with high-risk non-muscle invasive bladder cancer that hasn't spread. It aims to see if the vaccine can help the immune system better fight the cancer.
Bakersfield, CaliforniaAges 18 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Sun City, ArizonaAges 18 years+ - NCT04823897RecruitingPhase 1
Testing CCI-001 alone and with chemo for recurrent solid tumors
This early study tests whether CCI-001 can be given safely and may help shrink or control recurrent or metastatic (advanced) solid cancers. It checks the right dose first, then studies CCI-001 with standard chemotherapy in certain cancer types.
Edmonton, AlbertaAges 18 years+ - NCT06266338RecruitingPhase 2
Pembrolizumab and lenvatinib for recurrent or metastatic cervical cancer
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
Dallas, TexasAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant versus standard hormone therapy for early breast cancer
This trial compares a new medicine, elacestrant, to the usual hormone therapy for people with early-stage breast cancer that is hormone receptor-positive and HER2-negative, and who have a high chance of it coming back. The goal is to see if elacestrant works better at preventing the cancer from returning.
Daphne, AlabamaAges 18 years+ - NCT06963346RecruitingPhase 1
Bladder cancer trial: targeted drug plus immunotherapy before surgery
This trial tests a combination of a targeted drug (HDAC inhibitor, given directly into the bladder) and an immunotherapy (Durvalumab, given through a vein) before bladder removal surgery. It's for people with muscle-invasive bladder cancer who cannot take the chemo drug cisplatin.
Tampa, FloridaAges 18 years+ - NCT06388720RecruitingPhase 2
Two chemotherapy drugs for bladder cancer after BCG
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
Goyang-siAges 20 years+ - NCT07494864Recruiting
Urinary tract health and microbiome study
This study looks at how bacteria and the immune system affect the lower urinary tract. It includes healthy volunteers and people with various urinary conditions, like infections or bladder pain.
Zurich, Canton of ZurichAges 18 years+ - NCT07650240RecruitingPhase 2
PSMA Therapy and Hormone Treatment for Early-Stage Prostate Cancer Spread
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Rochester, MinnesotaAges 18 years+ - NCT04878666Recruiting
Breast cancer chest-wall recurrence quality of life with heat treatment
This trial studies how a special heating radiation treatment (“hyperthermia radiotherapy”) affects quality of life in people whose breast cancer has come back in the chest area. It may help show whether this treatment approach is tolerable and beneficial for everyday well-being.
Tübingen, Baden-WurttembergAges 18 years+ - NCT07081984RecruitingPhase 1
Testing TI-0093 for advanced HPV-16 positive cancers
This study tests a new drug, TI-0093, for people with HPV‑16 positive solid tumors (like head and neck or cervical cancer) that have come back or spread after standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
ShanghaiAges 18–75 - NCT06537154RecruitingPhase 2/Phase 3
Neoadjuvant therapy for bladder cancer with active surveillance
This trial tests whether people with muscle-invasive bladder cancer can safely avoid immediate surgery or radiation after a short course of chemotherapy. Instead, they would be closely monitored and only treated if the cancer comes back.
Vancouver, British ColumbiaAges 19 years+ - NCT05415631Recruiting
AI helps detect bladder tumors during bladder exam
This study tests an artificial-intelligence (AI) system during real-time bladder evaluation to better spot bladder tumors. It may help your care team find tumors more accurately during diagnosis or follow-up.
AmiensAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Goodyear, ArizonaAges 18 years+ - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT05104736RecruitingPhase 2
PT-112 for thymus gland tumors after prior chemotherapy
This trial studies PT-112, a new treatment, in people with thymoma or thymic carcinoma that has grown despite at least one prior platinum chemotherapy treatment. It may help shrink tumors or slow disease progression, especially when surgery is not possible.
Bethesda, MarylandAges 18–120
Hear when a new Bladder Cancer Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bladder cancer recurrence?
- Yes. Clin2 currently lists 158 recruiting bladder cancer recurrence studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bladder cancer recurrence trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bladder cancer recurrence trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.